We can’t show the full text here under this license. Use the link below to read it at the source.
PIONEER REAL Spain : A multicentre, prospective, real‐world study of oral semaglutide use in adults with type 2 diabetes
Real-world use of oral semaglutide in adults with type 2 diabetes in Spain
AI simplified
Abstract
Participants experienced an estimated average change in glycated hemoglobin (HbA) of -1.4%-points after oral semaglutide treatment.
- A total of 430 participants completed the study, with 392 on treatment at the end of the study.
- Body weight decreased by an estimated average of -6.8% following treatment.
- In participants using SGLT2 inhibitors, the average HbA change was -1.8%-points, compared to -1.2%-points in those not using SGLT2 inhibitors.
- Participants with type 2 diabetes duration of 5 years or less experienced a greater average HbA change than those with longer durations.
- At the end of the study, 77.4% of participants achieved an HbA level below 7%, and 33.3% had both a ≥1%-point reduction in HbA and a ≥5% reduction in body weight.
- Treatment satisfaction improved, and no new safety concerns were reported.
AI simplified
Key numbers
-1.4%-points
HbA Reduction
Change in HbA from baseline to end of study.
-6.8%
Body Weight Reduction
Change in body weight from baseline to end of study.
4.7 points
Treatment Satisfaction Improvement
Change in treatment satisfaction score at end of study.